Marker Therapeutics, Inc. (MRKR)
- Previous Close
4.0900 - Open
4.0600 - Bid 2.9000 x 200
- Ask 5.1000 x 200
- Day's Range
3.9799 - 4.2200 - 52 Week Range
1.1600 - 9.6800 - Volume
8,368 - Avg. Volume
17,619 - Market Cap (intraday)
35.476M - Beta (5Y Monthly) 1.54
- PE Ratio (TTM)
-- - EPS (TTM)
-1.5900 - Earnings Date May 14, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.75
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
markertherapeutics.comRecent News: MRKR
Performance Overview: MRKR
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRKR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRKR
Valuation Measures
Market Cap
36.46M
Enterprise Value
18.33M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.59
Enterprise Value/Revenue
3.41
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-248.76%
Return on Assets (ttm)
-35.36%
Return on Equity (ttm)
-83.47%
Revenue (ttm)
3.31M
Net Income Avi to Common (ttm)
-14.05M
Diluted EPS (ttm)
-1.5900
Balance Sheet and Cash Flow
Total Cash (mrq)
15.11M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-10.14M
Research Analysis: MRKR
Company Insights: MRKR
MRKR does not have Company Insights